STING agonist-3
Based on 10 publication(s) in Google Scholar
STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 2138299-29-1
- Formula: C37H42N12O6
- Molecular Weight:750.81
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Activators Library
HY-L159
-
Immunopotentiator Compound Library
HY-L172
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) STING agonist-3
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Signal Transduct Target Ther. 2023 Feb 24;8(1):79. [Abstract]
- Signal Transduct Target Ther. 2021 Mar 15;6(1):123. [Abstract]
- Nature. 2022 Oct;610(7933):761-767. [Abstract]
- Science. 2026 Feb 26;391(6788):eads4405. [Abstract]
- J Clin Invest. 2024 Mar 19;134(10):e176748. [Abstract]
- Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]
- Clin Transl Med. 2020 Nov;10(7):e228. [Abstract]
- Hum Mutat. 2026 May 25:2026:8545428. [Abstract]
- SSRN. 2023 Nov 9.
Customer Validation & Images
-
WB
-
WB
Biological Activity
STING agonist-3 exhibits a pEC50 value of 7.5 in activation of STING in cells, this assay is determined using a luciferase reporter assay in human embryonic kidney cells (HEK293T) co-transfected with plasmids expressing STING and the enzyme firefly luciferase driven by the interferon stimulated response element promoter[1]. STING agonist-3 exhibits a pIC50 value of 9.5 in FRET assay. This is a competition binding assay which aims to determine the binding potency of molecules to the C-terminal Domain (CTD) of human STING[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2138299-29-1
-
Appearance Solid
-
Molecular Weight 750.81
-
Formula C37H42N12O6
-
Color White to off-white
-
SMILES
O=C(N)C1=CC=C(N(C(NC(C2=CC(C)=NN2CC)=O)=N3)C/C=C/CN4C5=C(N=C4NC(C6=CC(C)=NN6CC)=O)C=C(C(N)=O)C=C5OCCCO)C3=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Signal Transduct Target Ther
2023 Feb 24;8(1):79. PMID: 36823147 -
Signal Transduct Target Ther
Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins. [Abstract]2021 Mar 15;6(1):123. PMID: 33723219 -
Nature
2022 Oct;610(7933):761-767. PMID: 36261523
STING agonist-3 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Oct;610(7933):761-767. [Abstract]
STING and pSTING are enriched in CCVs obtained from STING agonist-3 (diABZI; 2.5 μM; for 2 hours)-stimulated cells, but not in those obtained from unstimulated cells.
STING agonist-3 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Oct;610(7933):761-767. [Abstract]
Incubate HeLa cGAS KO cells with NC siRNA or siRNAs targeting AP-1σ1 and AP-1 σ3 for 3 days and reconstitute with empty vector or HA-tagged AP-1σ1 are treated with 2.5 µM diABZI (STING agonist-3) for 0, 2, 4 h before analysis by western blot.
-
Science
2026 Feb 26;391(6788):eads4405. PMID: 41747053 -
J Clin Invest
STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. [Abstract]2024 Mar 19;134(10):e176748. PMID: 38502231 -
Cancer Immunol Res
Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]2023 May 3;11(5):583-599. PMID: 36921097 -
Clin Transl Med
Cytosolic DNA-STING-NLRP3 axis is involved in murine acute lung injury induced by lipopolysaccharide. [Abstract]2020 Nov;10(7):e228. PMID: 33252860 -
Hum Mutat
PLSCR3 Deficiency Triggers mtDNA-Driven cGAS-STING Activation to Potentiate Antitumor Immunity in Colorectal Cancer. [Abstract]2026 May 25:2026:8545428. PMID: 42206267 -
Solvent & Solubility
DMSO : 41.67 mg/mL (55.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (2.77 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Adam Kenneth, et al. Heterocyclic amides useful as protein modulators.patent WO2017175147A1
[2]. Ramanjulu JM, Pesiridis GS, Yang J, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity [published correction appears in Nature. 2019 Jun;570(7761):E53. doi: 10.1038/s41586-019-1265-5]. Nature. 2018;564(7736):439-443. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3319 mL | 6.6595 mL | 13.3189 mL | 33.2974 mL |
| 5 mM | 0.2664 mL | 1.3319 mL | 2.6638 mL | 6.6595 mL | |
| 10 mM | 0.1332 mL | 0.6659 mL | 1.3319 mL | 3.3297 mL | |
| 15 mM | 0.0888 mL | 0.4440 mL | 0.8879 mL | 2.2198 mL | |
| 20 mM | 0.0666 mL | 0.3330 mL | 0.6659 mL | 1.6649 mL | |
| 25 mM | 0.0533 mL | 0.2664 mL | 0.5328 mL | 1.3319 mL | |
| 30 mM | 0.0444 mL | 0.2220 mL | 0.4440 mL | 1.1099 mL | |
| 40 mM | 0.0333 mL | 0.1665 mL | 0.3330 mL | 0.8324 mL | |
| 50 mM | 0.0266 mL | 0.1332 mL | 0.2664 mL | 0.6659 mL |
STING agonist-3 Related Classifications
HY-103665 Related Classifications
Powered by Bioz